Lilly’s Omvoh shows promising one-year results in children with ulcerative colitis

The drug is currently approved for adults with moderately to severely active UC

Zealand Pharma reports positive Phase 1 results for investigational Kv1.3 ion channel blocker

Eyes broader autoimmune disease development

AstraZeneca to unveil pivotal cancer survival data from four Phase III trials at ESMO 2026

New results spanning gastric, lung and bladder cancers will spotlight experimental drug Sone-Ve

Lilly’s Omvoh delivers multi-dimensional disease control in ulcerative colitis & Crohn’s disease

The findings showed that 27.7% of Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control

NIPER Raebareli and AstraZeneca India partner to build clinical trial sites in 25 non-metro hubs

Department of Pharmaceuticals supports NIPER Raebareli–AstraZeneca collaboration to advance India’s clinical trial ecosystem under Biopharma SHAKTI

TREMFYA shows sustained Crohn’s disease remission through three years with rates reaching 94%

Both maintenance regimens recorded an 88% rate of 90-day corticosteroid-free clinical remission

Calluna Pharma completes dosing in Phase 2 IPF trial

The global trial has entered its final follow-up phase ahead of the anticipated topline results.

Merck to unveil first results from three pivotal cancer trials at ESMO 2026

The presentations will focus on investigational mRNA-based cancer immunotherapy intismeran autogene

Regeneron’s Pasatru shows sustained control of abnormal bone growth in rare disease trial

The findings from the Phase 3 OPTIMA trial were presented during a late-breaking oral session

Zydus’ experimental PBC drug shows stronger biochemical response in Phase 3 trial analysis

Saroglitazar is an investigational drug that has not been approved by the US FDA

Bristol Myers Squibb’s RYZ101 hits Phase 3 goal in hope for advanced neuroendocrine cancer patients

The results address a critical gap in treatment for patients whose cancer advances despite existing radiopharmaceutical therapy, leaving them with few effective options

Bristol Myers Squibb’s experimental lung disease drug meets key trial goal at lower dose

Bristol Myers Squibb said admilparant demonstrated a well-tolerated safety profile at both doses

Lilly study links psoriasis and obesity in new findings on combined Taltz & Zepbound treatment

Merck’s experimental eye drug matches standard therapy in major trial

The trial met its primary endpoint, with both remigromig doses independently demonstrating non-inferiority to monthly ranibizumab

Bristol Myers Squibb’s ZENBEXUS doubles progression-free survival in multiple myeloma trial

BMS said the safety profile of ZENBEXUS in combination with standard therapies was consistent with previously reported findings from the study.

FDA approves Roche's Tecentriq combo for stage III dMMR Colon Cancer

Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years

GSK’s ViiV says long-acting HIV treatment meets key Phase IIIb endpoint

The findings extend evidence from the LATITUDE study, which showed CAB + RPV LA was superior to daily oral therapy at maintaining viral suppression

Novartis to unveil new multiple sclerosis data at MSToronto2026

The company will unveil data from the Phase III REMODEL-1 and REMODEL-2 trials

AbbVie and Genmab report 51% reduction in disease progression risk in DLBCL trial

The safety profile of epcoritamab combined with R-CHOP was generally well tolerated and consistent with the known safety profiles of the individual treatments

Eyestem reports promising Phase 2 results for cell therapy targeting vision loss in dry AMD

Eyecyte-RPE has demonstrated an overall safety profile in Phase 2 consistent with that seen in the earlier Phase 1 trial